These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 11772129)

  • 1. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary hormonal manipulation of prostate cancer.
    Small EJ; Harris KA
    Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):24-30. PubMed ID: 12198635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary hormonal manipulation of prostate cancer.
    Harris KA; Small EJ
    Curr Urol Rep; 2001 Jun; 2(3):224-30. PubMed ID: 12084269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options in hormone-refractory metastatic prostate carcinoma.
    Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E
    Tumori; 2004; 90(6):535-46. PubMed ID: 15762353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives.
    Autorino R; Di Lorenzo G; Damiano R; De Placido S; D'Armiento M
    Urol Int; 2003; 70(1):1-14. PubMed ID: 12566808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of prostate cancer. A review.
    Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
    Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State-of-the-art treatment of metastatic hormone-refractory prostate cancer.
    Goodin S; Rao KV; DiPaola RS
    Oncologist; 2002; 7(4):360-70. PubMed ID: 12185298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in advanced prostate cancer.
    Beedassy A; Cardi G
    Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy.
    Akaza H; Moore MA; Chang SJ; Cheng C; Choi HY; Esuvaranathan K; Hinotsu S; Hong SJ; Kim CS; Kim WJ; Murai M; Naito S; Soebadi D; Song JM; Umbas R; Usami M; Xia S; Yang CR
    Asian Pac J Cancer Prev; 2007; 8(1):3-12. PubMed ID: 17477764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group.
    Winquist E; Waldron T; Berry S; Ernst DS; Hotte S; Lukka H
    BMC Cancer; 2006 May; 6():112. PubMed ID: 16670021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug development in prostate cancer.
    Ripple GH; Wilding G
    Semin Oncol; 1999 Apr; 26(2):217-26. PubMed ID: 10597732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.